Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0018681 (headache)
 56,091 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A 50-year-old man developed a granular cell tumor (GCT) of the right hemisphere (parieto-occipital) with visual deterioration and headache. Two months after surgery the tumor relapsed with diffuse infiltration of the right hemisphere, the corpus callosum and the adjacent left hemisphere. Subsequently, radiotherapy (5000 rads) was applied. Controls two and four months after the radiotherapy did not show any signs of the tumor in the computerized tomogram (CT). Light- and electronmicroscopy showed typical type I (small) and type II (large) granular cells with irregularly rounded or oval nuclei, abundant cytoplasm and PAS positive granules. Immunohistochemistry was positive with anti-alpha-1-antichymotrypsin (ACT) and the MB2 antibody. A survey of the relevant literature is given with special emphasis on the impact of the results of immunohistochemistry on the histogenesis of the CNS granular cell. Finally, some aspects of the therapy of GCTs will be discussed.
 ...
PMID:Malignant intracerebral granular cell tumor reacts positively with anti-alpha-1-antichymotrypsin and the MB2 antibody: a clue to the histogenesis of the brain granular cell? 216 Mar 45

Twenty-six malignant lymphomas involving the central nervous system were studied. Eleven were primary (P) and 15 were systemic (S). Eight cases (3 P, 5 S) occurred in immunocompromised patients. Age at presentation in immunocompromised patients was typically younger than in the nonimmunocompromised patients. Presenting complaints of central nervous system involvement included headache, seizures, personality changes, memory lapses, ataxia, cranial nerve symptoms, and impaired consciousness. Cerebrospinal fluid involvement was seen only in 3 S cases. In 8 of the P cases, the diagnosis was first established at autopsy; in 6 of the S cases, central nervous system involvement was first documented at autopsy. Survival was longer in treated patients than in those who received no therapy (5 months in P cases and 9.3 months in S cases; 2.3 months without therapy). Regardless of therapy, the average survival of immunocompromised patients was 2.4 months. The majority of cases were multifocal. Of the P cases, 1 was of low histologic grade, 9 were of intermediate grade, and 1 was of high grade. Of the S cases, 5 were of low grade, 9 were of intermediate grade, and 1 was of high grade. Immunophenotypic studies were performed on formalin-fixed, paraffin-embedded tissue with antisera against common leukocyte antigen (all reactive), B-cell markers (L26, MB2, LN1, and LN2), T-cell markers (UCHL1 and MT1), Leu-M1, Leu-7, and HLA-DR (LN3). Two S cases were of T-cell phenotype; all others were of B-cell derivation. Eleven cases were HLA-DR positive (all of B-cell phenotype). One T-cell lymphoma was reactive for Leu-7. All cases were nonreactive for Leu-M1. All cases in immunosuppressed patients and all P cases were of B-cell phenotype.
 ...
PMID:Central nervous system lymphomas. Immunohistochemical and clinicopathologic study of 26 autopsy cases. 252 37